Cancer Therapy
Phase I healthy volunteer trial of HYB2055 completed
Published in Gene Therapy Weekly, May 6th, 2004
In this trial, this drug candidate was safe and biologically active. HYB2055 is a second-generation immunomodulatory oligonucleotide (IMO) that combines a novel DNA structure, referred to as an Immunomer, and a synthetic CpR immunomodulatory motif.
"HYB2055 has exhibited an excellent safety profile over the 32-fold range of dosages evaluated in this phase I trial," said R. Russell Martin, MD, senior vice president of drug development at Hybridon. "Evidence of biological activity by several parameters was seen at all dose levels administered and we have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-05-06)
More Articles from Gene Therapy Weekly
- Bioengineering
Reengineered salivary glands act as bioreactors for systemic gene therapies - Cancer Therapy
Therapy combining cisplatin and overexpressed CAD promotes tumor destruction - Gene Therapy
HIV/gammaretrovirus-based STAR vector packaging system evaluated - Hematology
Antisense RNA molecules select for molecules linked to sickle cell disease - Neuroscience
Genetically modified olfactory ensheathing cells facilitate spinal cord repair - Vector Development
Folate receptor-targeted lipid vesicles ferry oligodeoxynucleotides to tumors - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
